TY  - JOUR
AU  - Subošić, Branko
AU  - Kotur-Stevuljević, Jelena
AU  - Brborić, Jasmina
AU  - Janković, Tamara
AU  - Milenković, Marina
AU  - Ivković, Branka
AU  - Kostadinović, Jelena
AU  - Savić, Jelena
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5146
AB  - The interplay between oxidative stress and inflammation is implicated in many chronic diseases including Alzheimer`s disease, cardiovascular diseases, diabetes and cancer. Thirteen β-hydroxy-β-arylalkanoic acids were previously synthesized and evaluated for their anti-inflammatory activity. The aim of this study was to asses ex vivo antioxidant activity of synthesized acids, as well as ibuprofen and to identify the compounds with the most promising results for further investigation on their capacity to counteract in vivo oxidative stress triggered by inflammation. The antioxidant potential of tested compounds was evaluated by determining the concentrations of total antioxidative status, total oxidative status, prooxidant antioxidant balance and the total sulfhydryl groups. Z score statistics were used to calculate the summary scores for antioxidative activity, prooxidative activity and oxy score. The tested compounds and ibuprofen demonstrated mild prooxidative activity ex vivo. Seven acids with substituents on one benzene ring exhibited better results than ibuprofen and were selected for in vivo testing. In vivo results demonstrated better antioxidant protection compared to ex vivo results. Compound g which contains nitro group on the benzene ring demonstrated the lowest oxy score, and four compounds exhibited better results than ibuprofen.
PB  - Pakistan Journal of Pharmaceutical Sciences
T2  - Pakistan Journal of Pharmaceutical Sciences
T1  - Ex vivo and in vivo antioxidant activity of β-hydroxy-β-arylalkanoic acids
VL  - 36
IS  - 5
SP  - 1367
EP  - 1374
DO  - 10.36721/PJPS.2023.36.5.REG.1367-1374.1
ER  - 

@article{
author = "Subošić, Branko and Kotur-Stevuljević, Jelena and Brborić, Jasmina and Janković, Tamara and Milenković, Marina and Ivković, Branka and Kostadinović, Jelena and Savić, Jelena",
year = "2023",
abstract = "The interplay between oxidative stress and inflammation is implicated in many chronic diseases including Alzheimer`s disease, cardiovascular diseases, diabetes and cancer. Thirteen β-hydroxy-β-arylalkanoic acids were previously synthesized and evaluated for their anti-inflammatory activity. The aim of this study was to asses ex vivo antioxidant activity of synthesized acids, as well as ibuprofen and to identify the compounds with the most promising results for further investigation on their capacity to counteract in vivo oxidative stress triggered by inflammation. The antioxidant potential of tested compounds was evaluated by determining the concentrations of total antioxidative status, total oxidative status, prooxidant antioxidant balance and the total sulfhydryl groups. Z score statistics were used to calculate the summary scores for antioxidative activity, prooxidative activity and oxy score. The tested compounds and ibuprofen demonstrated mild prooxidative activity ex vivo. Seven acids with substituents on one benzene ring exhibited better results than ibuprofen and were selected for in vivo testing. In vivo results demonstrated better antioxidant protection compared to ex vivo results. Compound g which contains nitro group on the benzene ring demonstrated the lowest oxy score, and four compounds exhibited better results than ibuprofen.",
publisher = "Pakistan Journal of Pharmaceutical Sciences",
journal = "Pakistan Journal of Pharmaceutical Sciences",
title = "Ex vivo and in vivo antioxidant activity of β-hydroxy-β-arylalkanoic acids",
volume = "36",
number = "5",
pages = "1367-1374",
doi = "10.36721/PJPS.2023.36.5.REG.1367-1374.1"
}

Subošić, B., Kotur-Stevuljević, J., Brborić, J., Janković, T., Milenković, M., Ivković, B., Kostadinović, J.,& Savić, J.. (2023). Ex vivo and in vivo antioxidant activity of β-hydroxy-β-arylalkanoic acids. in Pakistan Journal of Pharmaceutical Sciences
Pakistan Journal of Pharmaceutical Sciences., 36(5), 1367-1374.
https://doi.org/10.36721/PJPS.2023.36.5.REG.1367-1374.1

Subošić B, Kotur-Stevuljević J, Brborić J, Janković T, Milenković M, Ivković B, Kostadinović J, Savić J. Ex vivo and in vivo antioxidant activity of β-hydroxy-β-arylalkanoic acids. in Pakistan Journal of Pharmaceutical Sciences. 2023;36(5):1367-1374.
doi:10.36721/PJPS.2023.36.5.REG.1367-1374.1 .

Subošić, Branko, Kotur-Stevuljević, Jelena, Brborić, Jasmina, Janković, Tamara, Milenković, Marina, Ivković, Branka, Kostadinović, Jelena, Savić, Jelena, "Ex vivo and in vivo antioxidant activity of β-hydroxy-β-arylalkanoic acids" in Pakistan Journal of Pharmaceutical Sciences, 36, no. 5 (2023):1367-1374,
https://doi.org/10.36721/PJPS.2023.36.5.REG.1367-1374.1 . .

TY  - JOUR
AU  - Perović-Blagojević, Iva
AU  - Bojanin, Dragana
AU  - Ristovski-Kornic, Danijela
AU  - Marković, Jelena
AU  - Aleksić, Predrag
AU  - Subošić, Branko
AU  - Vekić, Jelena
AU  - Kotur-Stevuljević, Jelena
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4190
AB  - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of a highly
transmittable and heterogenic infection of the respiratory tract, characterized by a broad spectrum
of clinical manifestations with a different degree of severity. Medical laboratories play an
important role in early diagnosis and management of Coronavirus Disease 2019 (COVID-19)
patients. Indeed, the results of several laboratory tests are essential for assessing the severity of
the disease, selecting appropriate therapeutic procedures and monitoring treatment response.
Routine laboratory testing in COVID-19 patients includes biomarkers of acute phase reaction,
hematological and biochemical parameters that indicate tissue injury. The aim of this review
paper is to describe the role of these biomarkers in the diagnostics and management of adult and
pediatric COVID-19 patients.
AB  - Novi koronavirus SARS-CoV-2 je uzročnik lako prenosive i veoma heterogene infekcije respiratornog trakta, koju karakteriše širok spektar kliničkih manifestacija, različitog stepena težine. Medicinske laboratorije igraju važnu ulogu u ranoj dijagnostici i praćenju pacijenata sa COVID-19. Rezultati nekoliko laboratorijskih testova su od suštinskog značaja za procenu težine bolesti, odabir odgovarajućih terapijskih procedura i praćenje odgovora na terapiju. Rutinska laboratorijska ispitivanja kod pacijenata sa COVID-19 uključuju biomarkere akutne faze, hematološke i biohemijske parametre koji ukazuju na oštećenje tkiva. Cilj ovog rada je da se prikaže uloga tih biomarkera u dijagnostici i praćenju toka bolesti kod odraslih i pedijatrijskih pacijenata sa COVID-19.
PB  - Beograd : Savez farmaceutskih udruženja Srbije
T2  - Arhiv za farmaciju
T1  - The role of laboratory biomarkers in diagnostics and management of COVID-19 patients
T1  - Uloga laboratorijskih biomarkera u dijagnostici i praćenju pacijenata sa COVID-19
VL  - 72
IS  - 2
SP  - 231
EP  - 246
DO  - 10.5937/arhfarm72-36369
ER  - 

@article{
author = "Perović-Blagojević, Iva and Bojanin, Dragana and Ristovski-Kornic, Danijela and Marković, Jelena and Aleksić, Predrag and Subošić, Branko and Vekić, Jelena and Kotur-Stevuljević, Jelena",
year = "2022",
abstract = "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of a highly
transmittable and heterogenic infection of the respiratory tract, characterized by a broad spectrum
of clinical manifestations with a different degree of severity. Medical laboratories play an
important role in early diagnosis and management of Coronavirus Disease 2019 (COVID-19)
patients. Indeed, the results of several laboratory tests are essential for assessing the severity of
the disease, selecting appropriate therapeutic procedures and monitoring treatment response.
Routine laboratory testing in COVID-19 patients includes biomarkers of acute phase reaction,
hematological and biochemical parameters that indicate tissue injury. The aim of this review
paper is to describe the role of these biomarkers in the diagnostics and management of adult and
pediatric COVID-19 patients., Novi koronavirus SARS-CoV-2 je uzročnik lako prenosive i veoma heterogene infekcije respiratornog trakta, koju karakteriše širok spektar kliničkih manifestacija, različitog stepena težine. Medicinske laboratorije igraju važnu ulogu u ranoj dijagnostici i praćenju pacijenata sa COVID-19. Rezultati nekoliko laboratorijskih testova su od suštinskog značaja za procenu težine bolesti, odabir odgovarajućih terapijskih procedura i praćenje odgovora na terapiju. Rutinska laboratorijska ispitivanja kod pacijenata sa COVID-19 uključuju biomarkere akutne faze, hematološke i biohemijske parametre koji ukazuju na oštećenje tkiva. Cilj ovog rada je da se prikaže uloga tih biomarkera u dijagnostici i praćenju toka bolesti kod odraslih i pedijatrijskih pacijenata sa COVID-19.",
publisher = "Beograd : Savez farmaceutskih udruženja Srbije",
journal = "Arhiv za farmaciju",
title = "The role of laboratory biomarkers in diagnostics and management of COVID-19 patients, Uloga laboratorijskih biomarkera u dijagnostici i praćenju pacijenata sa COVID-19",
volume = "72",
number = "2",
pages = "231-246",
doi = "10.5937/arhfarm72-36369"
}

Perović-Blagojević, I., Bojanin, D., Ristovski-Kornic, D., Marković, J., Aleksić, P., Subošić, B., Vekić, J.,& Kotur-Stevuljević, J.. (2022). The role of laboratory biomarkers in diagnostics and management of COVID-19 patients. in Arhiv za farmaciju
Beograd : Savez farmaceutskih udruženja Srbije., 72(2), 231-246.
https://doi.org/10.5937/arhfarm72-36369

Perović-Blagojević I, Bojanin D, Ristovski-Kornic D, Marković J, Aleksić P, Subošić B, Vekić J, Kotur-Stevuljević J. The role of laboratory biomarkers in diagnostics and management of COVID-19 patients. in Arhiv za farmaciju. 2022;72(2):231-246.
doi:10.5937/arhfarm72-36369 .

Perović-Blagojević, Iva, Bojanin, Dragana, Ristovski-Kornic, Danijela, Marković, Jelena, Aleksić, Predrag, Subošić, Branko, Vekić, Jelena, Kotur-Stevuljević, Jelena, "The role of laboratory biomarkers in diagnostics and management of COVID-19 patients" in Arhiv za farmaciju, 72, no. 2 (2022):231-246,
https://doi.org/10.5937/arhfarm72-36369 . .